Biological pipelines are evolving from standard antibody formats to next-generation biologics. These advances increase pressure on cell line construction timelines and create challenges in identifying cell lines that meet production needs. As a result, highly optimized cell technologies are required to address these demands.

In this webinar, we use internal data and a customer case study to demonstrate how the GS System® and GS piggyBac® technology can rise to the challenge of producing novel IgG-engineered cancer immunotherapies.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center